Statistical comparisons were carried out using analysis of variance (ANOVA) testing, post-hoc Tukeys multiple comparisons testing or t -testing, depending on the experimental set up, as described in figure legends
Diabetes, Obesity and Metabolism, 27 (4), 22512258
But there are a few major caveats to keep in mind: This was a comparison of data from separate clinical trials of both medicationsnot a head-to-head comparison
Those who already drink light to moderate amounts, who have not experienced negative health effects, can probably continue drinking moderately as long as they are not at risk for becoming heavy drinkers and continue to be healthy
The peptide might look dissolved, but functionally, it could be useless
Myth #4: GLP-1 agonists are only for diabetics There is a widespread belief that GLP-1 agonists are exclusively for people with diabetes, leading to confusion about their use in weight loss for non-diabetic individuals